| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 11.92▲ | 11.86▲ | 11.87▲ | 11.65▲ | 12.04▼ |
| MA10 | 11.86▲ | 11.86▲ | 11.76▲ | 11.49▲ | 12.49▼ |
| MA20 | 11.85▲ | 11.71▲ | 11.56▲ | 12.03▼ | 13.00▼ |
| MA50 | 11.86▲ | 11.54▲ | 11.51▲ | 12.68▼ | 13.37▼ |
| MA100 | 11.68▲ | 11.50▲ | 11.74▲ | 12.92▼ | 10.32▲ |
| MA200 | 11.53▲ | 11.78▲ | 12.09▼ | 13.23▼ | 14.88▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.020▲ | 0.012▲ | 0.053▲ | 0.036▲ | -0.200▼ |
| RSI | 67.122▲ | 67.234▲ | 63.637▲ | 49.228▼ | 46.056▼ |
| STOCH | 92.974▲ | 50.890 | 82.261▲ | 46.109 | 20.561 |
| WILL %R | -9.091▲ | -4.717▲ | -2.513▲ | -37.278 | -74.178 |
| CCI | 193.952▲ | 139.464▲ | 88.288 | 34.609 | -84.659 |
|
Monday, October 26, 2026 04:00 AM
Global Phase 2b/3 Study Will Evaluate Symptom Duration and Hospitalization Rates in Adult Outpatients at High Risk of Severe Outcomes from RSV Topline Phase 2b Data Expected in 2027 Enanta ...
|
|
Monday, October 26, 2026 01:27 AM
Enanta doses the first patient in its Phase 2b/3 RESOLVE RSV trial of zelicapavir in high-risk adults, with initial topline results expected in 2027.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 26/10/26 | 11.75 | 12.05 | 11.67 | 12.005 | 386,143 |
| 23/10/26 | 11.57 | 11.68 | 10.97 | 11.64 | 228,231 |
| 22/10/26 | 11.31 | 11.625 | 11.085 | 11.62 | 200,625 |
| 21/10/26 | 11.64 | 11.85 | 11.24 | 11.31 | 166,827 |
| 20/10/26 | 11.43 | 11.85 | 11.41 | 11.67 | 164,922 |
| 19/10/26 | 11.14 | 11.76 | 11.00 | 11.41 | 293,409 |
| 16/10/26 | 11.65 | 11.65 | 10.945 | 11.10 | 215,413 |
| 15/10/26 | 11.34 | 11.75 | 11.22 | 11.47 | 178,425 |
| 14/10/26 | 11.44 | 11.565 | 11.145 | 11.18 | 227,614 |
| 13/10/26 | 12.37 | 12.37 | 11.39 | 11.52 | 173,991 |
|
|
||||
|
|
||||
|
|